Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amarin ( (AMRN) ) has shared an announcement.
David Keenan, Ph.D., has been appointed as the Executive Vice President and Chief Operating Officer of Amarin Corporation, effective October 17, 2025. Dr. Keenan, who joined Amarin in May 2022, brings over 30 years of leadership experience in the biopharmaceutical and medical device industries, with expertise in operations, quality management, and international M&A.
The most recent analyst rating on (AMRN) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.
Spark’s Take on AMRN Stock
According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.
Amarin’s stock score is primarily influenced by its financial challenges, including declining revenues and negative cash flows. While technical indicators show strong momentum, overbought conditions could lead to a pullback. The earnings call provided a positive outlook with strategic initiatives, but U.S. market challenges remain a concern.
To see Spark’s full report on AMRN stock, click here.
More about Amarin
Amarin Corporation plc operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutics for cardiovascular health.
Average Trading Volume: 76,666
Technical Sentiment Signal: Hold
Current Market Cap: $420.6M
See more data about AMRN stock on TipRanks’ Stock Analysis page.